ESMO E-Learning: How to Treat Multiple Myeloma With So Many Drugs

Learning Objectives

  • To provide an update on diagnosis, staging and general management strategy in patients with multiple myeloma
  • To understand a wealth of considerations on which treatment to use in different clinical scenarios among patients with multiple myeloma
  • To provide an update on recently emerged drugs and those in the pipeline for patients with multiple myeloma

After two years E-Learning modules are no longer considered current. There is therefore no CME test associated with this E-Learning module.

Title Duration Content CME Points CME Test
How to Treat Multiple Myeloma With So Many Drugs 54 min. 56 slides 1 Take Test
Jesús San-Miguel
Read more

In this E-learning module, the author provides important clinical insights on how to find an appropriate balance between treatment efficacy, toxicity and cost of treatment in the plethora of newly available drugs for patients with multiple myeloma.

In that regard, for very elderly patients (those older than 80-85 years), the goal of the treatment should be to ensure quality of life (QoL) and avoid additional costs of expensive treatments. For fit elderly patients (65-80 years) and young ones with severe co-morbidities, the treatment goal should be to prolong survival and ensure QoL. For young patients (those younger than 65 years), the goal should be to investigate therapeutic schemes with a cure in the horizon, in reference centres and large cooperative groups.

Given the high rates of complete response seen in patients with multiple myeloma with new treatment approaches, the International Myeloma Working Group (IMWG) has defined new response categories of minimal residual disease negativity to allow uniform reporting. Besides the IMWG criteria, the author also presents the Revised International Staging System for multiple myeloma.

The author elaborates in a didactic way the smoldering multiple myeloma entity from the aspect of risk of transformation into symptomatic multiple myeloma and curative strategy for high risk smoldering patients.

In terms of myeloma treatment, the author divides the talk into two parts: newly diagnosed patients and relapsed setting. Furthermore, the treatment options in newly diagnosed patients are highlighted separately for transplant candidates (young) and non-transplant candidates (elderly). Strategies at relapse depend on the type of relapse, efficacy of previous treatments and toxicity of previous treatments. All treatment strategies are illustrated by findings from the clinical trials.

This E-Learning module is an excellent informative and educational tool for all those who would like to keep abreast of novel and emerging drugs in multiple myeloma.

This E-Learning module was published in 2016 and expired in 2019.

Last update: 29 November 2016

The author has reported Advisory Board relationship with: Millennium Pharmaceuticals, Celgene, Novartis, Onyx Pharmaceuticals, Janssen, Bristol-Myers Squibb, MSD and Amgen